Foresight Diagnostics Presents Independent Validation of its CLARITY Minimal Residual Disease (MRD) Assay in Multicenter Study of Frontline DLBCL at the 2025 ASCO Annual Meeting

The data shows the prognostic value of Foresight CLARITY MRD detection at the end of frontline DLBCL in one of its largest prospective, real-world studies to date Data will be presented as an oral presentation on Friday, May 30, 2025, at 2:45 p.m. CT BOULDER, Colo., May 22, 2025…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks